Multivariate Analysis of Adverse Reactions and Recipient Profiles in COVID-19 Booster Vaccinations: A Prospective Cohort Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Investigation Methods for Adverse Reactions and the Backgrounds of the Recipients
2.3. Statistical Analysis
2.4. Ethical Review
3. Results
3.1. Profile of Study Participants and Adverse Reactions to Vaccinations
3.2. Comparison of Adverse Reactions to the Third and Fourth Doses
3.3. Association between Adverse Reactions and Recipient Profiles in Booster Vaccination
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Callaway, E. The coronavirus is mutating—Does it matter? Nature 2020, 585, 174–177. [Google Scholar] [CrossRef] [PubMed]
- Martin, D.P.; Weaver, S.; Tegally, H.; San, J.E.; Shank, S.D.; Wilkinson, E.; Lucaci, A.G.; Giandhari, J.; Naidoo, S.; Pillay, Y.; et al. The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages. Cell 2021, 184, 5189–5200.e7. [Google Scholar] [CrossRef] [PubMed]
- Telenti, A.; Hodcroft, E.B.; Robertson, D.L. The evolution and biology of SARS-CoV-2 variants. Cold Spring Harb. Perspect. Med. 2022, 12, a041390. [Google Scholar] [CrossRef]
- Stefanizzi, P.; Ferorelli, D.; Scazzi, F.L.; Di Lorenzo, A.; Martinelli, A.; Trinchera, C.; Moscara, L.; Miniello, E.; Di Bona, D.; Tafuri, S. Allergic adverse events following immunization: Data from post-marketing surveillance in Apulia region (South of Italy). Front. Immunol. 2023, 14, 1074246. [Google Scholar] [CrossRef] [PubMed]
- Tafuri, S.; Fortunato, F.; Gallone, M.S.; Stefanizzi, P.; Calabrese, G.; Boccalini, S.; Martinelli, D.; Prato, R. Systematic causality assessment of adverse events following HPV vaccines: Analysis of current data from Apulia region (Italy). Vaccine 2018, 36, 1072–1077. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention. People with Certain Medical Conditions. Available online: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html (accessed on 8 September 2023).
- Centers for Disease Control and Prevention. Factors that Affect Your Risk of Getting Very Sick from COVID-19. Available online: https://www.cdc.gov/coronavirus/2019-ncov/your-health/risks-getting-very-sick.html (accessed on 10 July 2023).
- World Health Organization. COVID-19 Vaccine Tracker and Landscape. Available online: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed on 11 July 2023).
- Ministry of Health, Labour and Welfare. COVID-19 Vaccines. Available online: https://www.mhlw.go.jp/stf/covid-19/vaccine.html (accessed on 11 July 2023).
- Moscara, L.; Venerito, V.; Martinelli, A.; Di Lorenzo, A.; Toro, F.; Violante, F.; Tafuri, S.; Stefanizzi, P. Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: An Italian observational study. Vaccine 2023, 41, 5655–5661. [Google Scholar] [CrossRef] [PubMed]
- Chi, W.Y.; Li, Y.D.; Huang, H.C.; Chan, T.E.H.; Chow, S.Y.; Su, J.H.; Ferrall, L.; Hung, C.F.; Wu, T.C. COVID-19 vaccine update: Vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J. Biomed. Sci. 2022, 29, 82. [Google Scholar] [CrossRef]
- World Health Organization. Side Effects of COVID-19 Vaccines. Available online: https://www.who.int/news-room/feature-stories/detail/side-effects-of-covid-19-vaccines (accessed on 5 July 2023).
- Fazlollahi, A.; Zahmatyar, M.; Noori, M.; Nejadghaderi, S.A.; Sullman, M.J.M.; Shekarriz-Foumani, R.; Kolahi, A.A.; Singh, K.; Safiri, S. Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev. Med. Virol. 2022, 32, e2318. [Google Scholar] [CrossRef]
- Al-Ali, D.; Elshafeey, A.; Mushannen, M.; Kawas, H.; Shafiq, A.; Mhaimeed, N.; Mhaimeed, O.; Mhaimeed, N.; Zeghlache, R.; Salameh, M.; et al. Cardiovascular and haematological events post COVID-19 vaccination: A systematic review. J. Cell. Mol. Med. 2022, 26, 636–653. [Google Scholar] [CrossRef]
- Shah, A.; Coiado, O.C. COVID-19 vaccine and booster hesitation around the world: A literature review. Front. Med. 2023, 9, 1054557. [Google Scholar] [CrossRef]
- Elnaem, M.H.; Taufek, N.H.M.; Ab Rahman, N.S.; Nazar, N.I.M.; Zin, C.S.; Nuffer, W.; Turner, C.J. COVID-19 vaccination attitudes, perceptions, and side effect experiences in Malaysia: Do age, gender, and vaccine type matter? Vaccines 2021, 9, 1156. [Google Scholar] [CrossRef] [PubMed]
- Urakawa, R.; Isomura, E.T.; Matsunaga, K.; Kubota, K.; Ike, M. Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: A cross-sectional study. BMC Infect. Dis. 2022, 22, 179. [Google Scholar] [CrossRef] [PubMed]
- Urakawa, R.; Isomura, E.T.; Matsunaga, K.; Kubota, K. Young age, female sex, and no comorbidities are risk factors for adverse reactions after the third dose of BNT162b2 COVID-19 vaccine against SARS-CoV-2: A prospective cohort study in Japan. Vaccines 2022, 10, 1357. [Google Scholar] [CrossRef]
- National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Available online: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (accessed on 10 September 2023).
- Ruggieri, A.; Anticoli, S.; D’Ambrosio, A.; Giordani, L.; Viora, M. The influence of sex and gender on immunity, infection and vaccination. Annali dell’Istituto Superiore di Sanita 2016, 52, 198–204. [Google Scholar] [PubMed]
- Trigunaite, A.; Dimo, J.; Jørgensen, T.N. Suppressive effects of androgens on the immune system. Cell. Immunol. 2015, 294, 87–94. [Google Scholar] [CrossRef]
- Ciarambino, T.; Para, O.; Giordano, M. Immune system and COVID-19 by sex differences and age. Women’s Health 2021, 17, 17455065211022262. [Google Scholar] [CrossRef]
- Ciarambino, T.; Barbagelata, E.; Corbi, G.; Ambrosino, I.; Politi, C.; Lavalle, F.; Ruggieri, A.; Moretti, A. Gender differences in vaccine therapy: Where are we in COVID-19 pandemic? Monaldi Arch. Chest Dis. 2021, 91, 1669. [Google Scholar] [CrossRef]
- Fink, A.L.; Klein, S.L. Sex and gender impact immune responses to vaccines among the elderly. Physiology 2015, 30, 408–416. [Google Scholar] [CrossRef]
- Lord, J.M. The effect of aging of the immune system on vaccination responses. Hum. Vaccines Immunother. 2013, 9, 1364–1367. [Google Scholar] [CrossRef]
- Menni, C.; May, A.; Polidori, L.; Louca, P.; Wolf, J.; Capdevila, J.; Hu, C.; Ourselin, S.; Steves, C.J.; Valdes, A.M.; et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: A prospective community study from the ZOE COVID Study. Lancet Infect. Dis. 2022, 22, 1002–1010. [Google Scholar] [CrossRef]
- Lu, J.G. Two large-scale global studies on COVID-19 vaccine hesitancy over time: Culture, uncertainty avoidance, and vaccine side-effect concerns. J. Pers. Soc. Psychol. 2023, 124, 683–706. [Google Scholar] [CrossRef] [PubMed]
- Centers for Disease Control and Prevention. Getting Your COVID-19 Vaccine. Available online: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect.html (accessed on 20 September 2023).
- Department of Health and Aged Care, Australian Government. Clinical Recommendations for COVID-19 Vaccines. Available online: https://www.health.gov.au/our-work/covid-19-vaccines/advice-for-providers/clinical-guidance/clinical-recommendations (accessed on 20 September 2023).
- Ricci, E.; Glavasc, A.; Morandini, B.; Grassi, M.C.; La Torre, G. The Effectiveness of Paracetamol to Reduce the Post-Vaccination SARS-CoV-2 Adverse Effects in an Italian Vaccination Center. Vaccines 2023, 11, 1493. [Google Scholar] [CrossRef]
- Sheikh, A.; Kerr, S.; Woolhouse, M.; McMenamin, J.; Robertson, C.; EAVE II Collaborators. Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): A national cohort study with nested test-negative design. Lancet Infect. Dis. 2022, 22, 959–966. [Google Scholar] [CrossRef] [PubMed]
- Lin, L.; Zhao, Y.; Chen, B.; He, D. Multiple COVID-19 Waves and Vaccination Effectiveness in the United States. Int. J. Environ. Res. Public Health 2022, 19, 2282. [Google Scholar] [CrossRef] [PubMed]
Third Dose | Fourth Dose | |
---|---|---|
Mean age (SD, range) | 45.6 (12.9, 20–75) | 47.6 (13.1, 24–78) |
Sex | ||
Male: n (%) | 76 (39.2) | 46 (35.1) |
Female: n (%) | 118 (60.8) | 85 (64.9) |
Underlying diseases | ||
Yes: n (%) | 40 (20.6) | 33 (25.4) |
No: n (%) | 154 (79.4) | 98 (74.8) |
Vaccine type | ||
Monovalent Pfizer vaccine (original): n (%) | 178 (91.8) | 48 (36.6) |
Monovalent Moderna vaccine (original): n (%) | 16 (8.2) | 72 (55.0) |
Bivalent Pfizer vaccine (BA.1/BA.4-5): n (%) | 0 | 10 (7.6) |
Bivalent Moderna vaccine (BA.1/BA.4-5): n (%) | 0 | 1 (0.8) |
Homologous or heterologous vaccination | ||
Homologous vaccination: n (%) | 175 (90.2) | 56 (42.7) |
Heterologous vaccination: n (%) | 19 (9.8) | 75 (57.3) |
Mean interval: days since last vaccination (SD, range) | 242.1 (19.3, 183–322) | 204.9 (26.4, 151–296) |
Grade 0 | Grade 1 | Grade 2 | Grade 3 | |
---|---|---|---|---|
Third Dose/Fourth Dose n (%) | Third Dose/Fourth Dose n (%) | Third Dose/Fourth Dose n (%) | Third Dose/Fourth Dose n (%) | |
Injection site reaction | 23 (11.9)/18 (13.7) | 103 (53.1)/67 (51.1) | 60 (30.9)/42 (32.1) | 8 (4.1)/4 (3.7) |
Fatigue | 57 (29.4)/41 (31.3) | 69 (35.6)/38 (29.0) | 51 (26.3)/45 (34.4) | 17 (8.8)/7 (5.3) |
Chills | 137 (70.6)/105 (80.2) | 43 (22.2)/24 (18.3) | 14 (7.2)/2 (1.5) | |
Fever | 143 (73.7)/100 (76.3) | 41 (21.1)/28 (21.4) | 10 (5.2)/3 (2.3) | |
Arthralgia | 117 (60.3)/83 (63.4) | 49 (25.3)/26 (19.8) | 21 (10.8)/18 (13.7) | 7 (3.6)/4 (3.1) |
Myalgia | 107 (55.2)/84 (64.1) | 61 (31.4)/29 (22.1) | 20 (10.3)/18 (13.7) | 6 (3.1)/0 (0) |
Headache | 95 (49.0)/70 (53.4) | 57 (29.4)/32 (24.4) | 33 (17.0)/23 (17.6) | 9 (4.6)/6 (4.6) |
Diarrhea | 185 (95.4)/126 (96.2) | 9 (4.6)/5 (3.8) | ||
Nausea | 160 (82.5)/112 (85.5) | 20 (10.3)/11 (8.4) | 9 (4.6)/8 (6.1) | 5 (2.6)/0 (0) |
Worst adverse reaction | 10 (5.2)/8 (6.1) | 85 (43.8)/55 (42.0) | 77 (39.7)/56 (42.7) | 22 (11.3)/12 (9.2) |
Grade 0 | Grade 1–3 | χ2 (df = 1) | OR (95% CI) | p Value | |
---|---|---|---|---|---|
Third Dose/Fourth Dose n (%) | Third Dose/Fourth Dose n (%) | ||||
Injection site reaction | 23 (11.9)/18 (13.7) | 171 (88.1)/113 (86.3) | 0.25 | 0.84 (0.44–1.64) | 0.62 |
Fatigue | 57 (29.4)/41 (31.3) | 137 (70.6)/90 (68.7) | 0.14 | 0.91 (0.56–1.48) | 0.71 |
Chills | 137 (70.6)/105 (80.2) | 57 (29.4)/26 (19.8) | 3.74 | 0.60 (0.35–1.01) | 0.05 |
Fever | 143 (73.7)/100 (76.3) | 51 (26.3)/31 (23.7) | 0.29 | 0.87 (0.52–1.45) | 0.59 |
Arthralgia | 117 (60.3)/83 (63.4) | 77 (39.7)/48 (36.6) | 0.31 | 0.88 (0.56–1.39) | 0.58 |
Myalgia | 107 (55.2)/84 (64.1) | 87 (44.8)/47 (35.9) | 2.60 | 0.69 (0.44–1.09) | 0.11 |
Headache | 95 (49.0)/70 (53.4) | 99 (51.0)/61 (46.6) | 0.62 | 0.84 (0.54–1.30) | 0.43 |
Diarrhea | 185 (95.4)/126 (96.2) | 9 (4.6)/5 (3.8) | 0.13 | 0.82 (0.27–2.49) | 0.72 |
Nausea | 160 (82.5)/112 (85.5) | 34 (17.5)/19 (14.5) | 0.52 | 0.80 (0.43–1.47) | 0.47 |
Any adverse reaction | 10 (5.2)/8 (6.1) | 184 (94.8)/123 (93.9) | 0.14 | 0.84 (0.32–2.18) | 0.71 |
Number of Vaccinations | Age (10+) | Sex | Underlying Diseases | Type of Vaccination | Vaccination Interval (30+) | |
---|---|---|---|---|---|---|
OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
Univariate model | ||||||
Injection site reaction | 0.84 (0.44–1.64) | 0.52 ** (0.39–0.68) | 2.39 * (1.23–4.64) | 0.76 (0.36–1.61) | 1.98 (0.94–4.21) | 1.29 (0.92–1.81) |
Fatigue | 0.91 (0.56–1.48) | 0.72 ** (0.60–0.87) | 2.11 ** (1.30–3.42) | 0.72 (0.42–1.26) | 0.93 (0.61–1.42) | 1.09 (0.85–1.39) |
Chills | 0.60 (0.35–1.01) | 0.69 ** (0.56–0.85) | 2.11 ** (1.21–3.69) | 0.39 * (0.19–0.80) | 0.93 (0.59–1.47) | 1.28 (0.98–1.67) |
Fever | 0.87 (0.52–1.45) | 0.72 ** (0.58–0.88) | 2.07 * (1.18–3.61) | 0.25 ** (0.11–0.57) | 1.05 (0.67–1.65) | 1.13 (0.87–1.47) |
Arthralgia | 0.88 (0.56–1.39) | 0.70 ** (0.59–0.85) | 1.56 (0.98–2.51) | 0.44 ** (0.25–0.80) | 0.89 (0.59–1.34) | 1.12 (0.89–1.42) |
Myalgia | 0.69 (0.44–1.09) | 0.87 (0.73–1.03) | 1.49 (0.94–2.37) | 0.54 * (0.31–0.94) | 0.75 (0.49–1.13) | 1.25 (0.99–1.58) |
Headache | 0.84 (0.54–1.30) | 0.67 ** (0.56–0.80) | 3.98 ** (2.46–6.46) | 0.61 (0.36–1.03) | 1.29 (0.87–1.93) | 1.34 * (1.06–1.69) |
Diarrhea | 0.82 (0.27–2.49) | 0.51 ** (0.31–0.85) | 1.53 (0.47–4.98) | 0.26 (0.03–1.99) | 1.31 (0.54–3.16) | 0.89 (0.51–1.54) |
Nausea | 0.80 (0.43–1.47) | 0.87 (0.69–1.10) | 2.63 ** (1.30–5.34) | 0.31 * (0.12–0.82) | 0.92 (0.53–1.59) | 1.22 (0.89–1.66) |
Any adverse reaction | 0.84 (0.32–2.18) | 0.27 ** (0.16–0.45) | 4.72 ** (1.64–13.60) | 0.34 * (0.13–0.88) | 1.64 (0.58–4.66) | 1.19 (0.73–1.95) |
Multivariate model | ||||||
Injection site reaction | 0.51 (0.16–1.66) | 0.54 ** (0.39–0.73) | 1.54 (0.74–3.22) | 1.52 (0.65–3.52) | 2.05 (0.79–5.35) | 0.84 (0.51–1.40) |
Fatigue | 1.06 (0.46–2.42) | 0.74 ** (0.60–0.91) | 1.94 * (1.16–3.26) | 1.02 (0.56–1.87) | 0.73 (0.41–1.30) | 0.93 (0.65–1.33) |
Chills | 0.51 (0.21–1.23) | 0.75 * (0.60–0.94) | 1.84 * (1.03–3.31) | 0.52 (0.25–1.11) | 1.14 (0.61–2.11) | 0.94 (0.64–1.37) |
Fever | 0.84 (0.36–2.00) | 0.79 * (0.63–0.99) | 1.77 (0.99–3.17) | 0.31 ** (0.14–0.73) | 1.00 (0.54–1.84) | 0.94 (0.65–1.38) |
Arthralgia | 1.09 (0.50–2.36) | 0.74 ** (0.61–0.91) | 1.35 (0.82–2.23) | 0.57 (0.31–1.06) | 0.76 (0.44–1.33) | 0.98 (0.70–1.38) |
Myalgia | 1.06 (0.50–2.26) | 0.95 (0.78–1.15) | 1.45 (0.89–2.37) | 0.60 (0.33–1.08) | 0.69 (0.40–1.20) | 1.17 (0.84–1.63) |
Headache | 0.89 (0.40–1.97) | 0.74 ** (0.60–0.91) | 3.39 ** (2.04–5.62) | 0.93 (0.51–1.69) | 1.14 (0.65–1.98) | 1.16 (0.82–1.64) |
Diarrhea | 0.18 (0.02–1.30) | 0.47 ** (0.27–0.82) | 1.26 (0.37–4.33) | 0.42 (0.05–3.41) | 2.35 (0.66–8.41) | 0.41 (0.17–1.03) |
Nausea | 1.12 (0.41–3.03) | 1.02 (0.79–1.31) | 2.52 * (1.22–5.24) | 0.35 * (0.13–0.93) | 0.78 (0.38–1.60) | 1.18 (0.76–1.81) |
Any adverse reaction | 0.51 (0.08–3.02) | 0.25 ** (0.14–0.46) | 2.43 (0.70–8.47) | 0.95 (0.31–2.96) | 0.86 (0.21–3.54) | 0.55 (0.26–1.14) |
Number of Vaccinations | Age (10+) | Sex | Underlying Diseases | Cross-Vaccination | Vaccination Interval (30+) | |
---|---|---|---|---|---|---|
OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
Multivariate model | ||||||
Injection site reaction | 0.68 (0.22–2.05) | 0.53 ** (0.39–0.72) | 1.61 (0.77–3.37) | 1.52 (0.66–3.51) | 0.64 (0.23–1.75) | 0.90 (0.55–1.48) |
Fatigue | 1.08 (0.51–2.31) | 0.73 ** (0.59–0.90) | 1.97 * (1.17–3.30) | 1.02 (0.56–1.87) | 1.64 (0.86–3.15) | 0.92 (0.65–1.30) |
Chills | 0.50 (0.23–1.12) | 0.75 * (0.60–0.94) | 1.84 * (1.03–3.29) | 0.52 (0.25–1.10) | 0.81 (0.41–1.60) | 0.94 (0.65–1.37) |
Fever | 0.82 (0.37–1.80) | 0.79 * (0.63–0.99) | 1.76 (0.98–3.15) | 0.31 ** (0.14–0.73) | 0.95 (0.48–1.86) | 0.94 (0.65–1.36) |
Arthralgia | 0.91 (0.45–1.85) | 0.74 ** (0.61–0.90) | 1.31 (0.80–2.17) | 0.58 ** (0.31–1.07) | 1.10 (0.60–2.02) | 0.95 (0.68–1.31) |
Myalgia | 0.93 (0.46–1.85) | 0.94 (0.78–1.14) | 1.42 (0.87–2.32) | 0.61 * (0.34–1.09) | 1.35 (0.74–2.47) | 1.13 (0.82–1.55) |
Headache | 1.04 (0.50–2.15) | 0.74 ** (0.60–0.91) | 3.47 ** (2.09–5.75) | 0.93 (0.51–1.69) | 1.07 (0.58–2.00) | 1.19 * (0.85–1.67) |
Diarrhea | 0.28 (0.05–1.55) | 0.48 ** (0.28–0.83) | 1.29 (0.38–4.37) | 0.40 (0.05–3.22) | 0.57 (0.15–2.16) | 0.46 (0.19–1.11) |
Nausea | 1.18 (0.48–2.96) | 1.01 (0.78–1.31) | 2.57 * (1.24–5.34) | 0.35 * (0.13–0.93) | 1.61 (0.70–3.69) | 1.18 (0.77–1.79) |
Any adverse reaction | 0.90 (0.17–4.84) | 0.22 ** (0.12–0.43) | 2.85 (0.80–10.20) | 0.95 * (0.30–2.97) | 3.44 (0.67–17.59) | 0.59 (0.29–1.22) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Urakawa, R.; Isomura, E.T.; Matsunaga, K.; Kubota, K. Multivariate Analysis of Adverse Reactions and Recipient Profiles in COVID-19 Booster Vaccinations: A Prospective Cohort Study. Vaccines 2023, 11, 1513. https://doi.org/10.3390/vaccines11101513
Urakawa R, Isomura ET, Matsunaga K, Kubota K. Multivariate Analysis of Adverse Reactions and Recipient Profiles in COVID-19 Booster Vaccinations: A Prospective Cohort Study. Vaccines. 2023; 11(10):1513. https://doi.org/10.3390/vaccines11101513
Chicago/Turabian StyleUrakawa, Ryuta, Emiko Tanaka Isomura, Kazuhide Matsunaga, and Kazumi Kubota. 2023. "Multivariate Analysis of Adverse Reactions and Recipient Profiles in COVID-19 Booster Vaccinations: A Prospective Cohort Study" Vaccines 11, no. 10: 1513. https://doi.org/10.3390/vaccines11101513
APA StyleUrakawa, R., Isomura, E. T., Matsunaga, K., & Kubota, K. (2023). Multivariate Analysis of Adverse Reactions and Recipient Profiles in COVID-19 Booster Vaccinations: A Prospective Cohort Study. Vaccines, 11(10), 1513. https://doi.org/10.3390/vaccines11101513